Introduction
Throughout the history of the world, the ones who had confronted the bitterest face of poverty and war had always been the women. As known poverty and war affects human health either directly or indirectly, the effects of this condition on health and status of women in the society should not be ignored. This study intends to cast light on the effects of war and poverty on the reproductive health of women. For this purpose, the face of war affecting the women, the problem of immigration, inequalities in distribution of income based on gender and the effects of all these on the reproductive health of women will be addressed.
War and Women's Health
Famine, synonymous with war and poverty, is clearer for women; war means deep disadvantages such as full destruction, loss of future and uncertainty for women. Wars are conflicts that destroy families, societies and cultures that negatively affect the health of community and cause violation of human rights. According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1) . War has many negative effects on human health. One of these is its effect of shortening the average human life. According to the data of WHO, the average human life is 68.1 years for males and 72.7 years for females. It is being thought that severe military conflicts in Africa shorten the expected lifetime for more than 2 years. In general, WHO had calculated that 269 thousand people had died in 1999 due to the effect of wars and that loss of 8.44 million healthy years of life had occurred (2, 3) . Wars negatively affect the provision of health services. Health institutions such as hospitals, laboratories and health centers are direct targets of war. Moreover, the wars cause the migration of qualified health employees, and thus the health services hitches. Assessments made indicate that the effect of destruction in the infrastructure of health continues for 5-10 years even after the finalization of conflicts (3) . Due to resource requirements in the restructuring investments after war, the share allocated to health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and children. While deaths depending on direct violence affect the male population, the indirect deaths kill children, women and elders more. In Iraq between 1990-1994, infant deaths had shown this reality in its more bare form with an increase of 600% (4). The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5) . As the result of wars and armed conflicts, women are
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Women on the Other Side of War and Poverty: Its Effect on the Health of Reproduction action of the parenteral fat emulsions is the accumulation in macrophages and impairment of their various functions (6) . Although the exact immune mechanism by which intralipid acts is not clear, the soybean oil may be the active component that inhibits pro-inflammatory mediators, specifically type 1 T-helper cells (7).
Kalfarentzos et al studied the differences between fat emulsions, intralipid 10%, and intralipid 30% and compared the resulting plasma levels of different lipid components. There were no differences between them. However, intralipid 30% had more lipid components in comparison to intralipid 10%. The fat emulsion with greater concentration of triglyceride has been found to be safe and is used for sick patients requiring total parenteral nutrition (7) .
Imbalance of the immune system during implantation or pregnancy may lead to implantation failure or miscarriage and therefore the usage of immunosuppressive or immunomodulatory agents can prevent immunological occurrence (6) .
Intralipids have immunosuppressive effects (6) and thus the intravenous intralipid injection affects the proliferation and function of immune cells including the lymphocytes (8) and by inhibiting the IL-2, it decreases the activation signals for T and B lymphocyte (9) .
When used in ICSI cycles with patients with RIF, intravenous intralipid 20% infusion improves the clinical pregnancy, the implantation, and the live birth rate (10) .
MIF is a distressing condition affecting couples. Immunotherapeutic agents such as immunomodulators and immunosuppressive are new factors but they have been used for managing patients with MIF and have been found to eliminate the damaging reactions against the fetus (8, 9) . Few studies have been conducted to assess intralipid use in patients undergoing assisted reproductive technologies (ART).
The aim of this study is to evaluate the effect of fat emulsion intralipid 20% on reproductive outcomes of patients with MIF undergoing ART.
Materials and Methods
Thirty women with MIF participated in this study. They were at reproductive endocrine and infertility medicine department (REIMD) at women specialized hospital, King Fahad Medical City (KFMC) from January 2015 to December 2016. All charts of women with 3 or more unsuccessful IVF cycles who received 20% intralipid fat emulsion, age less than 45, and normal uterine cavity were reviewed. The charts were excluded from our analysis if any of the following conditions were recorded in the chart: a patient with medical condition contraindicating the use of intralipid infusion, uterine fibroid, endometrial polyp, endometriosis and hydrosalpinx, intrauterine adhesion and uterine anomalies, deficiency of protein C, protein S, factor V Leiden, antiphospholipid syndrome (lupus anticoagulant), anticardiolipin antibodies (immunoglobulin G or M) [IgG or IgM]), and other recognized thrombophilic conditions. Statistical Analysis MS Excel 2010 and SPSS 22.0 software were used for data analysis. Categorical variables were expressed as frequencies and percentages and were analyzed using chi-square tests. Metric data was presented as the mean, +/-standard deviation, and analyzed using independent sample t tests. All statistical tests were 2-tailed. The hypotheses were tested based on the P value, where P less than 0.05 was considered as statistically significant.
Results
Thirty patients were included in the study, 27 of them underwent IVF -ICSI cycle and 3 underwent frozen embryo transfer (FET) cycles. The latter was evaluated for the effect of administration of intravenous intralipid on pregnancy outcome.
Patient demographics and clinical characteristics were demonstrated in Table 1 . The identified causes of infertility were tubal factor in (16.7%, n = 5), polycystic ovary (PCO) (13.3%, n = 4), male (33.3%, n = 10), anovulatory (6.6 %, n = 2), unexplained (13.3%, n = 4), multiple (13.3, n = 4), and other ones such as endometriosis and fibroid (3.3%, n = 1). Six patients started with long protocol, 21 of them with antagonist protocol, and 3 with FET cycle. Higher pregnancy rate was found with the use of long protocol in comparison to the short antagonist protocol. Use of intralipid 20% did not affect embryo grading or yield higher number of frozen embryos. Table 2 shows the descriptive analysis and laboratory testing of study parameters. Median age for wife was 37 years which ranges from 31 to45 years, median age of husband was 40 years within the range of 31-60 years, and median duration of infertility was 8 years ranges from 3 to18 years. Median follicle-stimulating hormone (FSH) level was 5.72 IU/L, luteinizing hormone (LH) level was 6.35 IU/L, prolactin level was 254 mIU/L, and thyroid stimulating hormone (TSH) level was 2.23 mIU/L. The median body mass index (BMI) of patients was 29.1 kg/m 2 . Table 3 demonstrates the impact and association of the parameters with pregnancy outcomes. Pregnancy rate with the use of intralipid intravenous infusion was achieved in 43.3% of the patients and 56.6% did not get pregnant. There was no significant statistical difference in pregnancy outcome in relation to measured hormonal profiles (Table 4) .
Discussion
The infusion of 20% intralipid solution has been studied with results showing better outcomes in women with RIF (5). In a non-randomized trial on patients with MIF who had an elevated T helper-1 (TH1) cytokine, a 50% pregnancy rate and 46% clinical pregnancy rate were reported (5). The intralipid infusion was given between days 4 and 9 of the ovarian stimulation and was re-given within 7 days of a positive pregnancy test. However, the beneficial effects of the infusion, have shown to be decreased with further treatment cycles. The most amount of reduction in clinical pregnancy rates was obvious in the third IVF treatment cycle and hence immunological tests should be considered in those cases (6) .
Clark in 1994 concluded that in a clinical trial intralipid had been successful in treating patients with recurrent miscarriages. It was found that both IVIG and intralipid could suppress NK cell cytotoxicity with equal efficacy in a in vitro assay that made the intralipid a cost-effective option (11) . In a more recent study that was published in 2013, impaired endometrial receptivity was assessed and the beneficial effect of intralipid infusion in the presence of increased natural killer cell cytotoxic activity in patients with recurrent implantation failure was identified (12) .
Another study showed intralipid suppresses in vivo abnormal NK-cell functional activity and implied that Intralipid can modulate abnormal NK activity in women with reproductive failure (10) . In 2016, AbdolmohammadiVahid et al recommended the use of immunosuppressive or immunomodulator agents since the imbalance of the immune system during implantation or pregnancy may lead to implantation failure or miscarriage (13) . Thus using intralipid with its inhibitory immunological effect may improve pregnancy outcomes (13) .
In our study pregnancy rate with the use of intralipid infusion showed no statistical significance between both groups.
Other studies in the literature have shown no difference in reproductive outcomes in women with recurrent implantation failure who received intravenous immunoglobulin or intralipid. One of them is a casecontrol study that was terminated because of their initial data that reported no pregnancies among the intralipid group compared to untreated control group (14) . Many have recommended the need for larger randomized controlled trials to prove the efficacy of intralipid before it can be recommended for routine use. In 2016, Dakhly et al demonstrated that Intralipid administration did not increase the frequency of chemical pregnancy (15) . However, they recommended that findings related to ongoing pregnancy and live birth should be investigated further (15) . They also defined the use of intralipid as a valuable therapy and advised that its use should be based solely on randomized controlled trial (16) . Needless to say, the present study is not without limitations. The main limitations are the small sample size, lack of the control group, and the retrospective study design.
A randomized controlled study with a larger number of patients is needed. More conclusive evidence in terms of the best dose and timing of intralipid for the patients with MIF is also required.
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